CDER Office of Compliance looks to secure drug, API supply chain
This article was originally published in The Gold Sheet
The Office of Compliance in FDA's Center for Drug Evaluation and Research is considering contracting for help to get its planned Secure Supply Chain Pilot Program up and running. The program would provide incentives for drug manufacturers to develop secure routes for importing finished drugs and active pharmaceutical ingredients. The idea, FDA said in an Aug. 1 sources-sought notice, is to enable FDA field personnel to focus on the less secure supply routes in their efforts to prevent importation of diverted and counterfeit drugs. Other tasks for the contractor could include helping with preparing draft guidances on improving the safety, efficacy, quality and purity of imported drugs, and helping with Good Importer Practices policies, pandemic influenza preparedness and agreements with other countries
You may also be interested in...
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.
Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.